Ibrutinib is a potent irreversible inhibitor of Bruton's tyrosin kinase (BTK) that has demonstrated exceptional safety and efficacy as a monotherapy in CLL patients [14, 15]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.